Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
NCT07379151 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 450
Last updated 2026-06-03
Summary
This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.
Conditions
- Meningoccocal Disease
Sponsors & Collaborators
-
Serum Institute of India Pvt. Ltd.
lead INDUSTRY
Eligibility
- Min Age
- 7 Years
- Max Age
- 36 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-05-05
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- Mali
- The Gambia
Study Locations
More Related Trials
-
Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old
NCT05739292 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months
NCT00601731 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
NCT00474487 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
NCT00560313 ·Status: COMPLETED ·Phase: PHASE2
-
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults
NCT00715910 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
NCT01272180 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
NCT02878291 ·Status: UNKNOWN ·Phase: PHASE1
-
Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®
NCT00269477 ·Status: COMPLETED ·Phase: PHASE2
-
The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination
NCT01962207 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
NCT05252715 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
NCT00856297 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India
NCT01547715 ·Status: COMPLETED ·Phase: PHASE3
-
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
NCT01274897 ·Status: COMPLETED ·Phase: PHASE3
-
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
NCT00258856 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
NCT01018732 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants
NCT06647407 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612
NCT00390143 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents
NCT00262041 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults
NCT02810340 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
NCT00450437 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds
NCT01154088 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612
NCT00427908 ·Status: COMPLETED ·Phase: PHASE2
-
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
NCT01823536 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
NCT02199691 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine
NCT04689191 ·Status: UNKNOWN ·Phase: PHASE3